Ceva Animal Health Gallops Into Equine Market
Altresyn, ConfidenceEQ and Tildren are among the first products offered through Ceva’s new equine division.
ConfidenceEQ is a synthetic pheromone that replicates the signals a mare sends to her foal, according to manufacturer Ceva Animal Health.
Ceva Animal Health, fresh off its takeover of veterinary drug maker Sogeval, has launched an equine division with four veterinarians in key sales roles.
The company’s equine product catalog includes Altresyn (altrenogest), an oral solution formulated to suppress estrus in mares; ConfidenceEQ, a nostril gel designed to reduce stress; and Tildren (tiludronate disodium), which is used in the treatment of bone- and cartilage-related lameness.
A wide selection of treatments for pain and mobility, reproduction and behavior issues is scheduled to be introduced later this year, the Lenexa, Kan., company reported July 16.
“When Ceva decided to enter the U.S. animal health market, we knew the equine segment would be a strategic opportunity for growth based on the uniqueness of products like Tildren,” said Craig Wallace, Ceva Animal Health’s CEO and North American zone director. “Many members of our team have worked for years to ensure our successful entry into the equine market. We’re glad that day is finally here.”
Four equine veterinarians will serve as technical sales representatives. They are Simon Towl, DVM, who will oversee the Northeast region; Ashley Phelps, DVM (Southeast); Matt Klotz, DVM (Central); and Alina Vale, DVM (West).
“We want to ensure our customers have access to the educational resources and advice needed to guide them to successful outcomes when using our products in patients,” said Steve Hoffman, vice president of the equine business unit. “Having equine veterinarians in sales roles gives our customers easy access to the expertise available in our team.”
Ceva, whose companion animal products include the Vectra line of parasiticides and the pheromone products Adaptil and Feliway, acquired Sogeval Laboratories in late 2013. The merger of their U.S. operations is expected to be completed this month.